Mourad (Toporsian) Topors, Ph.D.

Mourad (Toporsian) Topors, Ph.D. is the Chief Scientific Officer at Repair Biotechnologies. He is an influential and innovative biomedical executive with experience leading and managing teams in translational medical research and drug development.

Repair Biotechnologies is a late preclinical-stage biotech company developing several first-in-class therapies based on the Cholesterol Degrading Platform (CDP). Mourad has been with the company since 2020 and oversees all scientific functions including basic and applied research, is responsible for the development of new processes, technologies and therapies, and recruits and manages qualified researchers and evaluates their performance.

Previously, between 2017 and 2020, he was Research and Biomarker Development Consultant at Topors and Associates Consulting. His work focused on the design and analysis of Pharmacokinetic-Pharmacodynamic (PKPD) studies using cutting-edge technologies and multi-disciplinary approaches for academia- and industry-based clients. He was also responsible for pre-clinical discovery protocols and reports, grant writing, investigational new drug applications and clinical summaries.

Between 2013 and 2017, Mourad was the Principal Investigator on Pulmonary/Critical Care at the Faculty at Harvard Medical School. During his time there, he was responsible for the inception, design, and execution of numerous translational research studies on rare diseases including pulmonary arterial hypertension (PAH) and hereditary hemorrhagic telangiectasia (HHT), and also preeclampsia and stem cell therapies in heart failure.

He also leveraged core competencies to establish key academic, clinical, and industry collaborations (including Pfizer, United Therapeutics, and Eli Lilly) to gain access to cutting-edge technologies, valuable patient samples, and clinical databases.

While he was there, he also joined Pfizer in 2015 as Project Architect and Team Leader for two and a half years. He oversaw a Pulmonary Arterial Hypertension (PAH) drug development program (immunotherapy), designed functional in vitro and in vivo PK/PD assays to prioritize and rank drug leads, and established clinical collaborations for PAH patient samples and defined biomarkers for patient stratification in Proof of Mechanism (PoM) and Proof of Concept (PoC) studies.

Mourad earned his Ph.D. in Experimental Medicine with a focus on Cardiopulmonary and Metabolic Disease from McGill University in 2001 with his thesis Vasoregulatory gene expression and vascular contractility following hypoxia. He did his Postdoctoral Fellowship on Vascular and Cardiopulmonary Disease in the Department of Immunology at the University of Toronto between 2001 and 2007.

He earned his Bachelor’s Degree of Science in Physiology from McGill University in 1993.

In 2007, he was Visiting Scientist in Cardio-renal and vascular diseases at Harvard Medical School.

After his Postdoc, Mourad became the Principal Investigator on Pulmonary and Critical Care at the Faculty at Harvard Medical School through Beth Israel Deaconess Medical Center. He was responsible for the inception, design, and execution of numerous translational research studies on rare diseases including pulmonary arterial hypertension (PAH) and hereditary hemorrhagic telangiectasia (HHT), and also preeclampsia and cancer. He also filed and was granted significant patents that would be licensed by multiple parties.

Mourad holds a number of patents regarding his work on Hepatocellular Carcinoma Research, Mitochondrial Flow, and Microbial Cholesterol Expression.

Since 2008 and until 2017, he was also Instructor in Medicine at the Harvard Medical School.

Mourad attended the largest gathering of longevity CEOs speaking on Developing Drugs for Cholesterol and Aging-Related Diseases at the Rejuvenation Startup Summit in Berlin in 2022, organized by Forever Healthy. He was also invited to the 2024 Summit as well. Read First set of speakers announced for Rejuvenation Startup Summit 2024.

He was also an invited speaker at the 7th Obesity and NASH Summit in 2023.

Mourad is a Member of the Liveforever Club.

Read Repair Biotechnologies – First-in-class Cell Therapy for Atherosclerosis and All Too Short Comments on the 10th Aging Research and Drug Discovery (ARDD) Meeting. Read Repair Biotechnologies Announces 48% Reversal of Atherosclerotic Plaque Lipids in a Preclinical Mouse Study.

Visit his LinkedIn profile. Follow him on Facebook and ResearchGate.